Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist, a class of injectable medication that activates two gut hormone receptors involved in blood sugar regulation and appetite. It’s the first drug in this dual-agonist class to receive FDA approval, distinguishing it from older medications like semaglutide (Ozempic, Wegovy) that target only one of those receptors.
How the Dual-Agonist Class Works
Your gut naturally releases two hormones after you eat: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). Both hormones signal your pancreas to release insulin when blood sugar rises. They also slow stomach emptying and reduce appetite. Most medications in this space, like semaglutide, mimic only GLP-1. Tirzepatide mimics both hormones simultaneously, which is why it’s classified as a dual agonist rather than a standard GLP-1 receptor agonist.
This dual action appears to produce stronger effects on both blood sugar and body weight than targeting GLP-1 alone. In head-to-head trials (the SURPASS program), tirzepatide delivered superior reductions in both A1C and body weight compared to semaglutide at all three doses tested.
What Mounjaro Is Approved to Treat
The FDA has approved Mounjaro specifically for improving blood sugar control in adults and children aged 10 and older with type 2 diabetes, used alongside diet and exercise. It is not approved as a standalone weight loss drug under the Mounjaro brand.
This is where branding matters. Eli Lilly sells the exact same molecule, tirzepatide, under a second brand name: Zepbound. Zepbound is approved for chronic weight management in adults with obesity (BMI of 30 or higher) or those who are overweight (BMI of 27 or higher) with at least one weight-related condition like high blood pressure or sleep apnea. Zepbound also has a separate approval for moderate to severe obstructive sleep apnea in adults with obesity. The two products are molecularly identical but carry different labels and often different insurance coverage.
How It Performed in Clinical Trials
The SURPASS trials tested tirzepatide across thousands of people with type 2 diabetes, comparing it to placebo, semaglutide, and insulin. The results were consistently strong. Up to 92% of participants reached an A1C below 7%, the standard target for most people with diabetes. More striking, up to 62% of participants achieved an A1C below 5.7%, which is the range typically seen in people without diabetes.
These results held up whether tirzepatide was used alone (SURPASS-1), compared to semaglutide (SURPASS-2), compared to insulin (SURPASS-3), or added on top of insulin therapy (SURPASS-5). Significant weight loss accompanied the blood sugar improvements across all trials.
Dosing and How It’s Taken
Mounjaro is a once-weekly injection given under the skin, typically in the abdomen, thigh, or upper arm. It comes in a prefilled pen, so you don’t handle needles or vials. The dose starts low and increases gradually to minimize side effects.
You begin at 2.5 mg weekly for the first four weeks. That starting dose is purely for your body to adjust and isn’t expected to control blood sugar on its own. After four weeks, the dose increases to 5 mg. From there, your prescriber can raise it in 2.5 mg steps every four weeks or longer, depending on how you respond. The maximum dose is 15 mg per week.
Common Side Effects
Gastrointestinal issues are the most frequent side effects, and they tend to increase at higher doses. In placebo-controlled trials, nausea affected 12% to 18% of people on tirzepatide (compared to 4% on placebo). Diarrhea occurred in 12% to 17% of treated patients, and vomiting in 5% to 9%. Decreased appetite, constipation, indigestion, and abdominal pain each affected roughly 5% to 11% depending on dose.
Women reported gastrointestinal side effects more often than men: about 47% of women on tirzepatide experienced at least one GI issue compared to 34% of men. These side effects are generally most noticeable during dose increases and often improve as your body adjusts. The gradual titration schedule is specifically designed to reduce this discomfort.
Boxed Warning and Safety Concerns
Mounjaro carries an FDA boxed warning, the most serious type, related to thyroid tumors. In rat studies, tirzepatide caused a dose-dependent increase in thyroid C-cell tumors. Whether this risk applies to humans is unknown, but the drug is contraindicated if you have a personal or family history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2.
Other serious but less common risks include inflammation of the pancreas (pancreatitis), low blood sugar (particularly when combined with insulin or certain other diabetes medications), kidney problems, severe stomach issues, and worsening of diabetic eye disease. A lump in the neck, difficulty swallowing, or persistent hoarseness are symptoms worth reporting promptly, as they can be signs of thyroid changes.
Storing Your Mounjaro Pen
Unused pens should be refrigerated between 36°F and 46°F (2°C to 8°C) and remain usable until the printed expiration date. If you need to travel or can’t refrigerate, an unused pen can stay at room temperature (up to 86°F or 30°C) for up to 30 days. Once you’ve used a pen, it can also be kept at room temperature for up to 30 days. Never freeze the pen; if it freezes, discard it.